Breast cancer (HER2 negative, oestrogen receptor positive, locally advanced or metastatic) - everolimus (with an aromatase inhibitor) (TA295)
Everolimus in combination with exemestane for treating advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy
What has NICE said?
NICE does not recommend everolimus, given with another drug called exemestane, for postmenopausal women with advanced breast cancer that is HER2 negative and hormone-receptor positive, and that has recurred or worsened after treatment with a non-steroidal aromatase inhibitor (another type of anticancer drug).
Why has NICE said this?
NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE applies special considerations to treatments that can extend the lives of people who are nearing the end of their life. NICE did not recommend everolimus because it does not provide enough benefit to patients to justify its high cost, and did not qualify for special consideration.
This page was last updated: 24 October 2013
- Web format
- Full Guidance (PDF)
- Defnyddio everolimus ar y cyd ag exemestane i drin canser datblygedig y fron: Gwybodaeth i'r cyhoedd (fformat MS Word)
Breast cancer (HER2 negative, oestrogen receptor positive, locally advanced or metastatic) - everolimus (with an aromatase inhibitor)
Information for the public
TA295 Breast cancer (HER2 negative, oestrogen receptor positive, locally advanced or metastatic) - everolimus (with an aromatase inhibitor): clinical audit tool
Implementation tools and resources
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.